MDT

+1.35%↑

116.8

+2.23%↑

VEEV

173.2

+0.02%↑

HQY

80.95

-0.2%↓

PHR.US

9.16

-2.24%↓

MDT

+1.35%↑

116.8

+2.23%↑

VEEV

173.2

+0.02%↑

HQY

80.95

-0.2%↓

PHR.US

9.16

-2.24%↓

MDT

+1.35%↑

116.8

+2.23%↑

VEEV

173.2

+0.02%↑

HQY

80.95

-0.2%↓

PHR.US

9.16

-2.24%↓

MDT

+1.35%↑

116.8

+2.23%↑

VEEV

173.2

+0.02%↑

HQY

80.95

-0.2%↓

PHR.US

9.16

-2.24%↓

MDT

+1.35%↑

116.8

+2.23%↑

VEEV

173.2

+0.02%↑

HQY

80.95

-0.2%↓

PHR.US

9.16

-2.24%↓

Kodu・Aktsiate loetelu・Krystal Biotech Inc

Krystal Biotech Inc

Suletud

SektorTervishoid

264.15 1.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

254.9

Max

264.34

Põhinäitajad
By Trading Economics
Sissetulek	-28M 51M
Müük	9.3M 107M
P/E Sektori keskmine	38.331 66.418
Kasumimarginaal	47.99
Töötajad	295
EBITDA	-10M 40M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.14% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-363M 7.7B
Eelmine avamishind	262.95
Eelmine sulgemishind	264.15

Uudiste sentiment

By Acuity

43%

57%

133 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

133.221 / 169.73 Toetus ja vastupanu

Krystal Biotech Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. apr 2026, 17:26 UTC

Uudisväärsed sündmused

EIA Raises Oil-Price Forecasts as War in Middle East Continues

7. apr 2026, 23:55 UTC

Market Talk

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Market Talk Roundup: Latest on U.S. Politics

7. apr 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

7. apr 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

7. apr 2026, 23:42 UTC

Market Talk

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:37 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

7. apr 2026, 23:15 UTC

Market Talk

Uudisväärsed sündmused

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

7. apr 2026, 23:04 UTC

Uudisväärsed sündmused

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

7. apr 2026, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. apr 2026, 23:03 UTC

Market Talk

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

7. apr 2026, 23:01 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

7. apr 2026, 22:58 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

7. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

7. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

7. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. apr 2026, 19:45 UTC

Market Talk

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

7. apr 2026, 19:17 UTC

Uudisväärsed sündmused

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

7. apr 2026, 19:16 UTC

Market Talk

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Global Energy Roundup: Market Talk

7. apr 2026, 19:07 UTC

Market Talk

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

7. apr 2026, 18:41 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

7. apr 2026, 18:40 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

7. apr 2026, 18:39 UTC

Omandamised, ülevõtmised, äriostud

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

7. apr 2026, 18:24 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 17:08 UTC

Market Talk

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

7. apr 2026, 16:21 UTC

Uudisväärsed sündmused

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

7. apr 2026, 16:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Krystal Biotech Inc Prognoos

Hinnasiht

By TipRanks

24.14% tõus

12 kuu keskmine prognoos

Keskmine 325 USD 24.14%

Kõrge 371 USD

Madal 284 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Krystal Biotech Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Krystal Biotech Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

133.221 / 169.73Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

133 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.